These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 21677231)

  • 21. Additional evidence of the abuse potential of bupropion.
    Reeves RR; Ladner ME
    J Clin Psychopharmacol; 2013 Aug; 33(4):584-5. PubMed ID: 23771197
    [No Abstract]   [Full Text] [Related]  

  • 22. Organic mental disorders associated with bupropion in three patients.
    Ames D; Wirshing WC; Szuba MP
    J Clin Psychiatry; 1992 Feb; 53(2):53-5. PubMed ID: 1541606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.
    Hewett K; Chrzanowski W; Jokinen R; Felgentreff R; Shrivastava RK; Gee MD; Wightman DS; O'Leary MC; Millen LS; Leon MC; Briggs MA; Krishen A; Modell JG
    J Psychopharmacol; 2010 Apr; 24(4):521-9. PubMed ID: 19164492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed-type (limb-truncal and orofacial) bupropion-associated dyskinesia.
    Ferentinos P; Christodoulou C; Rizos E; Douzenis A; Lykouras L
    J Clin Psychopharmacol; 2010 Oct; 30(5):644-6. PubMed ID: 20841971
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination antidepressant therapy for major depressive disorder: speed and probability of remission.
    Stewart JW; McGrath PJ; Blondeau C; Deliyannides DA; Hellerstein D; Norris S; Amat J; Pilowsky DJ; Tessier P; Laberge L; O'Shea D; Chen Y; Withers A; Bergeron R; Blier P
    J Psychiatr Res; 2014 May; 52():7-14. PubMed ID: 24485847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bupropion in the management of apathy.
    Corcoran C; Wong ML; O'Keane V
    J Psychopharmacol; 2004 Mar; 18(1):133-5. PubMed ID: 15107198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of panic disorder with bupropion in a patient with Parkinson's disease.
    Gebhardt S; Röttgers H; Bäcker A; Schu U; Krieg JC
    J Clin Pharm Ther; 2008 Oct; 33(5):575-7. PubMed ID: 18834374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
    Bech P; Fava M; Trivedi MH; Wisniewski SR; Rush AJ
    Acta Psychiatr Scand; 2012 Apr; 125(4):342-8. PubMed ID: 22077211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
    Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
    Blier P; Ward HE; Tremblay P; Laberge L; Hébert C; Bergeron R
    Am J Psychiatry; 2010 Mar; 167(3):281-8. PubMed ID: 20008946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of buspirone and bupropion in the treatment of depression.
    Fava M
    Psychother Psychosom; 2007; 76(5):311-2. PubMed ID: 17700052
    [No Abstract]   [Full Text] [Related]  

  • 33. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.
    Tomita T; Yasui-Furukori N; Kaneko S
    Clin Neuropharmacol; 2013; 36(5):175-6. PubMed ID: 24045610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bupropion normalizes cognitive performance in patients with depression.
    Gualtieri CT; Johnson LG
    MedGenMed; 2007 Jan; 9(1):22. PubMed ID: 17435629
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute psychosis after administration of bupropion hydrochloride (Zyban).
    Neumann M; Livak V; Paul HW; Laux G
    Pharmacopsychiatry; 2002 Nov; 35(6):247-8. PubMed ID: 12518275
    [No Abstract]   [Full Text] [Related]  

  • 36. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW; Pradko JF; Muir KT
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
    Yasui-Furukori N; Kaneko S
    Psychiatry Clin Neurosci; 2011 Jun; 65(4):384-5. PubMed ID: 21489048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Body dysmorphic disorder treated with bupropion: cases report.
    Nardi AE; Lopes FL; Valença AM
    Aust N Z J Psychiatry; 2005; 39(1-2):112. PubMed ID: 15660717
    [No Abstract]   [Full Text] [Related]  

  • 40. Transient citalopram-induced auditory hallucinations in a patient with Parkinson's disease and depression.
    Wand AP
    Aust N Z J Psychiatry; 2012 Feb; 46(2):178. PubMed ID: 22311539
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.